Home Healthcare Pharmaceuticals Anti-VEGF Therapeutics Market

Anti-VEGF Therapeutics Market Size, Share & Trends Analysis Report By Product (Eylea, Lucentis, Beovu, Vabysmo, Others), By Disease Type (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration, Myopic Choroidal Neovascularization) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: March 05, 2026 | Author: Debashree B | Format: | Report Code: SR4573DR | Pages: 150
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Anti-VEGF Therapeutics Market, By Product 2022-2034 (USD MILLION/ Units)
    1. Eylea
    2. Lucentis
    3. Beovu
    4. Vabysmo
    5. Others
  2. Anti-VEGF Therapeutics Market, By Disease Type 2022-2034 (USD MILLION/ Units)
    1. Macular Edema
    2. Diabetic Retinopathy
    3. Retinal Vein Occlusion
    4. Age-related Macular Degeneration
    5. Myopic Choroidal Neovascularization
  3. Regional Anti-VEGF Therapeutics Market
    1. North America
      1. North America Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
      2. North America Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Macular Edema
        2. Diabetic Retinopathy
        3. Retinal Vein Occlusion
        4. Age-related Macular Degeneration
        5. Myopic Choroidal Neovascularization
      3. U.S. Anti-VEGF Therapeutics Market
        1. U.S. Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. U.S. Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
      4. Canada Anti-VEGF Therapeutics Market
        1. Canada Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. Canada Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
    2. Europe
      1. Europe Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
      2. Europe Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Macular Edema
        2. Diabetic Retinopathy
        3. Retinal Vein Occlusion
        4. Age-related Macular Degeneration
        5. Myopic Choroidal Neovascularization
      3. U.K. Anti-VEGF Therapeutics Market
        1. U.K. Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. U.K. Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
      4. Germany Anti-VEGF Therapeutics Market
        1. Germany Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. Germany Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
      5. France Anti-VEGF Therapeutics Market
        1. France Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. France Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
      6. Spain Anti-VEGF Therapeutics Market
        1. Spain Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. Spain Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
      7. Italy Anti-VEGF Therapeutics Market
        1. Italy Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. Italy Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
      8. Russia Anti-VEGF Therapeutics Market
        1. Russia Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. Russia Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
      9. Nordic Anti-VEGF Therapeutics Market
        1. Nordic Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. Nordic Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
      10. Benelux Anti-VEGF Therapeutics Market
        1. Benelux Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. Benelux Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
      11. Rest of Europe Anti-VEGF Therapeutics Market
        1. Rest of Europe Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. Rest of Europe Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
    3. APAC
      1. APAC Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
      2. APAC Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Macular Edema
        2. Diabetic Retinopathy
        3. Retinal Vein Occlusion
        4. Age-related Macular Degeneration
        5. Myopic Choroidal Neovascularization
      3. China Anti-VEGF Therapeutics Market
        1. China Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. China Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
      4. Korea Anti-VEGF Therapeutics Market
        1. Korea Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. Korea Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
      5. Japan Anti-VEGF Therapeutics Market
        1. Japan Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. Japan Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
      6. India Anti-VEGF Therapeutics Market
        1. India Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. India Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
      7. Australia Anti-VEGF Therapeutics Market
        1. Australia Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. Australia Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
      8. Taiwan Anti-VEGF Therapeutics Market
        1. Taiwan Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. Taiwan Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
      9. South East Asia Anti-VEGF Therapeutics Market
        1. South East Asia Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. South East Asia Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
      10. Rest of Asia-Pacific Anti-VEGF Therapeutics Market
        1. Rest of Asia-Pacific Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. Rest of Asia-Pacific Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
    4. Middle East and Africa
      1. Middle East and Africa Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
      2. Middle East and Africa Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Macular Edema
        2. Diabetic Retinopathy
        3. Retinal Vein Occlusion
        4. Age-related Macular Degeneration
        5. Myopic Choroidal Neovascularization
      3. UAE Anti-VEGF Therapeutics Market
        1. UAE Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. UAE Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
      4. Turkey Anti-VEGF Therapeutics Market
        1. Turkey Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. Turkey Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
      5. Saudi Arabia Anti-VEGF Therapeutics Market
        1. Saudi Arabia Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. Saudi Arabia Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
      6. South Africa Anti-VEGF Therapeutics Market
        1. South Africa Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. South Africa Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
      7. Egypt Anti-VEGF Therapeutics Market
        1. Egypt Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. Egypt Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
      8. Nigeria Anti-VEGF Therapeutics Market
        1. Nigeria Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. Nigeria Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
      9. Rest of MEA Anti-VEGF Therapeutics Market
        1. Rest of MEA Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. Rest of MEA Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
    5. LATAM
      1. LATAM Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Vabysmo
        5. Others
      2. LATAM Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
        1. Macular Edema
        2. Diabetic Retinopathy
        3. Retinal Vein Occlusion
        4. Age-related Macular Degeneration
        5. Myopic Choroidal Neovascularization
      3. Brazil Anti-VEGF Therapeutics Market
        1. Brazil Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. Brazil Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
      4. Mexico Anti-VEGF Therapeutics Market
        1. Mexico Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. Mexico Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
      5. Argentina Anti-VEGF Therapeutics Market
        1. Argentina Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. Argentina Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
      6. Chile Anti-VEGF Therapeutics Market
        1. Chile Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. Chile Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
      7. Colombia Anti-VEGF Therapeutics Market
        1. Colombia Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. Colombia Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
      8. Rest of LATAM Anti-VEGF Therapeutics Market
        1. Rest of LATAM Anti-VEGF Therapeutics Market By Product 2022-2034 (USD MILLION/ Units)
          1. Eylea
          2. Lucentis
          3. Beovu
          4. Vabysmo
          5. Others
        2. Rest of LATAM Anti-VEGF Therapeutics Market By Disease Type 2022-2034 (USD MILLION/ Units)
          1. Macular Edema
          2. Diabetic Retinopathy
          3. Retinal Vein Occlusion
          4. Age-related Macular Degeneration
          5. Myopic Choroidal Neovascularization
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.